Combination product of dermal matrix, preconditioned human mesenchymal stem cells and timolol promotes wound healing in the porcine wound model
J Biomed Mater Res B Appl Biomater. 2022 Jan 31. doi: 10.1002/jbm.b.35022. Online ahead of print.ABSTRACTA combination product of human mesenchymal stem/stromal cells (MSCs) embedded in an extracellular matrix scaffold and preconditioned with hypoxia and the beta-adrenergic receptor antagonist, timolol, combined with sustained timolol application post implantation, has shown promising results for improving wound healing in a diabetic mouse model. In the present study, we extend those findings to the more translatable large animal porcine wound model and show that the combined treatment promotes wound reepithelialization in...
Source: Biomed Res - January 31, 2022 Category: Research Authors: Hsin-Ya Yang Fernando Fierro Daniel J Yoon Anthony Gallegos Stephanie L Osborn Alan V Nguyen Thomas R Peavy William Ferrier Linda Talken Betty W Ma Kristopher G Galang Andrea Medina Lopez Daniel R Fregoso Heather Stewart Eric A Kurzrock Athena M Soulika J Source Type: research
[ASAP] In Situ Gelling Electrospun Ocular Films Sustain the Intraocular Pressure-Lowering Effect of Timolol Maleate: In Vitro, Ex Vivo, and Pharmacodynamic Assessment
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.1c00766 (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - December 8, 2021 Category: Drugs & Pharmacology Authors: Ioannis I. Andreadis, Christina Karavasili, Angelos Thomas, Anastasia Komnenou, Manolis Tzimtzimis, Dimitrios Tzetzis, Dimitrios Andreadis, Nikolaos Bouropoulos, and Dimitrios G. Fatouros Source Type: research
TIMolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT) - study protocol of the prospective, randomized, double-blind, controlled cross-over TIM-HHT trial
CONCLUSION: TIM-HHT will evaluate the efficacy and safety of timolol as an additional treatment of epistaxis in HHT patients in a three-month trial period. Benzalkonium chloride is used as a placebo, which has no documented positive effect on the nasal mucosa and hence on epistaxis in HHT patients (in contrast to saline).TRIAL REGISTRATION: German Clinical Trials Register (DRKS), DRKS00020994. Registered on 10 March 2020.PMID:34864649 | DOI:10.3233/CH-211253 (Source: Clinical Hemorheology and Microcirculation)
Source: Clinical Hemorheology and Microcirculation - December 5, 2021 Category: Hematology Authors: Kornelia E C Andorfer Caroline T Seebauer Michael Koller Florian Zeman Mark Berneburg Ren é Fischer Veronika Vielsmeier Christopher Bohr Thomas S K ühnel Source Type: research
TIMolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT) - study protocol of the prospective, randomized, double-blind, controlled cross-over TIM-HHT trial
CONCLUSION: TIM-HHT will evaluate the efficacy and safety of timolol as an additional treatment of epistaxis in HHT patients in a three-month trial period. Benzalkonium chloride is used as a placebo, which has no documented positive effect on the nasal mucosa and hence on epistaxis in HHT patients (in contrast to saline).TRIAL REGISTRATION: German Clinical Trials Register (DRKS), DRKS00020994. Registered on 10 March 2020.PMID:34864649 | DOI:10.3233/CH-211253 (Source: Clinical Hemorheology and Microcirculation)
Source: Clinical Hemorheology and Microcirculation - December 5, 2021 Category: Hematology Authors: Kornelia E C Andorfer Caroline T Seebauer Michael Koller Florian Zeman Mark Berneburg Ren é Fischer Veronika Vielsmeier Christopher Bohr Thomas S K ühnel Source Type: research
TIMolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT) - study protocol of the prospective, randomized, double-blind, controlled cross-over TIM-HHT trial
CONCLUSION: TIM-HHT will evaluate the efficacy and safety of timolol as an additional treatment of epistaxis in HHT patients in a three-month trial period. Benzalkonium chloride is used as a placebo, which has no documented positive effect on the nasal mucosa and hence on epistaxis in HHT patients (in contrast to saline).TRIAL REGISTRATION: German Clinical Trials Register (DRKS), DRKS00020994. Registered on 10 March 2020.PMID:34864649 | DOI:10.3233/CH-211253 (Source: Clinical Hemorheology and Microcirculation)
Source: Clinical Hemorheology and Microcirculation - December 5, 2021 Category: Hematology Authors: Kornelia E C Andorfer Caroline T Seebauer Michael Koller Florian Zeman Mark Berneburg Ren é Fischer Veronika Vielsmeier Christopher Bohr Thomas S K ühnel Source Type: research
